The impact of metabolic syndrome on the responsiveness to α1‐blocker in men with BPH/LUTS

摘要: Summary Aims:  Increasing evidence has proposed the components of metabolic syndrome (MtS) as risk factors for development benign prostate hyperplasia (BPH); therefore, it is thought that MtS may play a role in lower urinary tract symptoms related to BPH (BPH/LUTS) aetiology. Considering closed relationships between and BPH/LUTS, possible patients with might have different drug responsiveness men BPH/LUTS. We prospectively investigated impact on α1-blocker BPH/LUTS. Methods:  enrolled total 109 mean (SD) age 59.8 (9.0) years, having volume 20 cm3 or greater moderate severe LUTS. All received doxazosin GITS (gastrointestinal therapeutic system) 4 mg once daily 12-week period treatment. The efficacy measurement was assessed by changes from baseline IPSS, maximum flow rate postvoid residual urine volume. responders were defined those who had IPSS decrease more than 4 points after 12 weeks treatment. Results:  Using multiple logistic regression analysis, our results showed an independent factor non-responder (OR = 4.26, p = 0.002). responder improvements significantly decreased number increased (p = 0.012 p = 0.026). Among components, abnormal fasting blood glucose (FBG) most (OR = 3.17, p = 0.020). Conclusion:  This study suggested presence negative Our are important BPH/LUTS did not initially respond strive reduce these